Details der Publikation - Chinese expert consensus on the diagnosis and treatment of HER2‐altered non

Chinese expert consensus on the diagnosis and treatment of HER2‐altered non–small cell lung cancer

Abstract Human epidermal growth factor receptor 2 (HER2) possesses tyrosine kinase activity and participates in cell growth, differentiation and migration, and survival. Its alterations, mainly including mutations, amplifications, and overexpression are associated with poor prognosis and are one of the major drivers in non–small cell lung cancer (NSCLC). Several clinical trials had been investigating on the treatments of HER2‐altered NSCLC, including conventional chemotherapy, programmed death 1 (PD‐1) inhibitors, tyrosine kinase inhibitors (TKIs) and antibody‐drug conjugates (ADCs), however, the results were either disappointing or encouraging, but inconsistent. Trastuzumab deruxtecan (T‐DXd) was recently approved by the Food and Drug Administration as the first targeted agent for treating HER2‐mutant NSCLC. Effective screening of patients is the key to the clinical application of HER2‐targeted agents such as TKIs and ADCs. Various testing methods are nowadays available, including polymerase chain reaction (PCR), next‐generation sequencing (NGS), fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), etc. Each method has its pros and cons and should be reasonably assigned to appropriate patients for diagnosis and guiding treatment decisions. To help standardize the clinical workflow, our expert group reached a consensus on the clinical management of HER2‐altered NSCLC, focusing on the diagnosis and treatment strategies..

Medienart:	E-Artikel

Erscheinungsjahr:	2023
Erschienen:	2023

Enthalten in:	Zur Gesamtaufnahme - volume:14
Enthalten in:	Thoracic Cancer - 14(2023), 1, Seite 91-104

Sprache:	Englisch

Beteiligte Personen:	Shirong Zhang [VerfasserIn] Wenxian Wang [VerfasserIn] Chunwei Xu [VerfasserIn] Yongchang Zhang [VerfasserIn] Xiuyu Cai [VerfasserIn] Qian Wang [VerfasserIn] Zhengbo Song [VerfasserIn] Ziming Li [VerfasserIn] Jinpu Yu [VerfasserIn] Wenzhao Zhong [VerfasserIn] Zhijie Wang [VerfasserIn] Jingjing Liu [VerfasserIn] Anwen Liu [VerfasserIn] Wen Li [VerfasserIn] Ping Zhan [VerfasserIn] Hongbing Liu [VerfasserIn] Tangfeng Lv [VerfasserIn] Liyun Miao [VerfasserIn] Lingfeng Min [VerfasserIn] Gen Lin [VerfasserIn] Long Huang [VerfasserIn] Jingping Yuan [VerfasserIn] Zhansheng Jiang [VerfasserIn] Xingxiang Pu [VerfasserIn] Chuangzhou Rao [VerfasserIn] Dongqing Lv [VerfasserIn] Zongyang Yu [VerfasserIn] Xiaoyan Li [VerfasserIn] Chuanhao Tang [VerfasserIn] Chengzhi Zhou [VerfasserIn] Junping Zhang [VerfasserIn] Hui Guo [VerfasserIn] Qian Chu [VerfasserIn] Rui Meng [VerfasserIn] Xuewen Liu [VerfasserIn] Jingxun Wu [VerfasserIn] Jin Zhou [VerfasserIn] Zhengfei Zhu [VerfasserIn] Weiwei Pan [VerfasserIn] Xiaowei Dong [VerfasserIn] Fei Pang [VerfasserIn] Kai Wang [VerfasserIn] Chao Yao [VerfasserIn] Guomin Lin [VerfasserIn] Site Li [VerfasserIn] Zhi Yang [VerfasserIn] Jiancheng Luo [VerfasserIn] Hongtao Jia [VerfasserIn] Xiuqing Nie [VerfasserIn] Liping Wang [VerfasserIn] Youcai Zhu [VerfasserIn] Xiao Hu [VerfasserIn] Yanru Xie [VerfasserIn] Xinqing Lin [VerfasserIn] Jing Cai [VerfasserIn] Yang Xia [VerfasserIn] Huijing Feng [VerfasserIn] Lin Wang [VerfasserIn] Yingying Du [VerfasserIn] Wang Yao [VerfasserIn] Xuefei Shi [VerfasserIn] Xiaomin Niu [VerfasserIn] Dongmei Yuan [VerfasserIn] Yanwen Yao [VerfasserIn] Jing Kang [VerfasserIn] Jiatao Zhang [VerfasserIn] Chao Zhang [VerfasserIn] Wenbin Gao [VerfasserIn] Jianhui Huang [VerfasserIn] Yinbin Zhang [VerfasserIn] Pingli Sun [VerfasserIn] Hong Wang [VerfasserIn] Mingxiang Ye [VerfasserIn] Dong Wang [VerfasserIn] Zhaofeng Wang [VerfasserIn] Bing Wan [VerfasserIn] Donglai Lv [VerfasserIn] Genhua Yu [VerfasserIn] Lin Shi [VerfasserIn] Yuanli Xia [VerfasserIn] Feng Gao [VerfasserIn] Xiaochen Zhang [VerfasserIn] Tao Xu [VerfasserIn] Wei Zhou [VerfasserIn] Haixia Wang [VerfasserIn] Zhefeng Liu [VerfasserIn] Nong Yang [VerfasserIn] Lin Wu [VerfasserIn] Qiming Wang [VerfasserIn] Guansong Wang [VerfasserIn] Zhuan Hong [VerfasserIn] Jiandong Wang [VerfasserIn] Meiyu Fang [VerfasserIn] Yong Fang [VerfasserIn] Yiping Zhang [VerfasserIn] Yong Song [VerfasserIn] Shenglin Ma [VerfasserIn] Wenfeng Fang [VerfasserIn] Yuanzhi Lu [VerfasserIn]

Links:	doi.org [kostenfrei] doaj.org [kostenfrei] doi.org [kostenfrei] Journal toc [kostenfrei] Journal toc [kostenfrei]

Themen:	Antibody‐drug conjugate Neoplasms. Tumors. Oncology. Including cancer and carcinogens Non–small cell lung cancer Precision medicine Targeted therapy Tyrosine receptor kinase

doi:	10.1111/1759-7714.14743

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	DOAJ000423130

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ000423130
003	DE-627
005	20230311010736.0
007	cr uuu---uuuuu
008	230225s2023 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1111/1759-7714.14743 \|2 doi
035			\|a (DE-627)DOAJ000423130
035			\|a (DE-599)DOAJe1bf776745ce4a09834d865a24396c56
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC254-282
100	0		\|a Shirong Zhang \|e verfasserin \|4 aut
245	1	0	\|a Chinese expert consensus on the diagnosis and treatment of HER2‐altered non–small cell lung cancer
264		1	\|c 2023
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Abstract Human epidermal growth factor receptor 2 (HER2) possesses tyrosine kinase activity and participates in cell growth, differentiation and migration, and survival. Its alterations, mainly including mutations, amplifications, and overexpression are associated with poor prognosis and are one of the major drivers in non–small cell lung cancer (NSCLC). Several clinical trials had been investigating on the treatments of HER2‐altered NSCLC, including conventional chemotherapy, programmed death 1 (PD‐1) inhibitors, tyrosine kinase inhibitors (TKIs) and antibody‐drug conjugates (ADCs), however, the results were either disappointing or encouraging, but inconsistent. Trastuzumab deruxtecan (T‐DXd) was recently approved by the Food and Drug Administration as the first targeted agent for treating HER2‐mutant NSCLC. Effective screening of patients is the key to the clinical application of HER2‐targeted agents such as TKIs and ADCs. Various testing methods are nowadays available, including polymerase chain reaction (PCR), next‐generation sequencing (NGS), fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), etc. Each method has its pros and cons and should be reasonably assigned to appropriate patients for diagnosis and guiding treatment decisions. To help standardize the clinical workflow, our expert group reached a consensus on the clinical management of HER2‐altered NSCLC, focusing on the diagnosis and treatment strategies.
650		4	\|a antibody‐drug conjugate
650		4	\|a non–small cell lung cancer
650		4	\|a precision medicine
650		4	\|a targeted therapy
650		4	\|a tyrosine receptor kinase
653		0	\|a Neoplasms. Tumors. Oncology. Including cancer and carcinogens
700	0		\|a Wenxian Wang \|e verfasserin \|4 aut
700	0		\|a Chunwei Xu \|e verfasserin \|4 aut
700	0		\|a Yongchang Zhang \|e verfasserin \|4 aut
700	0		\|a Xiuyu Cai \|e verfasserin \|4 aut
700	0		\|a Qian Wang \|e verfasserin \|4 aut
700	0		\|a Zhengbo Song \|e verfasserin \|4 aut
700	0		\|a Ziming Li \|e verfasserin \|4 aut
700	0		\|a Jinpu Yu \|e verfasserin \|4 aut
700	0		\|a Wenzhao Zhong \|e verfasserin \|4 aut
700	0		\|a Zhijie Wang \|e verfasserin \|4 aut
700	0		\|a Jingjing Liu \|e verfasserin \|4 aut
700	0		\|a Anwen Liu \|e verfasserin \|4 aut
700	0		\|a Wen Li \|e verfasserin \|4 aut
700	0		\|a Ping Zhan \|e verfasserin \|4 aut
700	0		\|a Hongbing Liu \|e verfasserin \|4 aut
700	0		\|a Tangfeng Lv \|e verfasserin \|4 aut
700	0		\|a Liyun Miao \|e verfasserin \|4 aut
700	0		\|a Lingfeng Min \|e verfasserin \|4 aut
700	0		\|a Gen Lin \|e verfasserin \|4 aut
700	0		\|a Long Huang \|e verfasserin \|4 aut
700	0		\|a Jingping Yuan \|e verfasserin \|4 aut
700	0		\|a Zhansheng Jiang \|e verfasserin \|4 aut
700	0		\|a Xingxiang Pu \|e verfasserin \|4 aut
700	0		\|a Chuangzhou Rao \|e verfasserin \|4 aut
700	0		\|a Dongqing Lv \|e verfasserin \|4 aut
700	0		\|a Zongyang Yu \|e verfasserin \|4 aut
700	0		\|a Xiaoyan Li \|e verfasserin \|4 aut
700	0		\|a Chuanhao Tang \|e verfasserin \|4 aut
700	0		\|a Chengzhi Zhou \|e verfasserin \|4 aut
700	0		\|a Junping Zhang \|e verfasserin \|4 aut
700	0		\|a Hui Guo \|e verfasserin \|4 aut
700	0		\|a Qian Chu \|e verfasserin \|4 aut
700	0		\|a Rui Meng \|e verfasserin \|4 aut
700	0		\|a Xuewen Liu \|e verfasserin \|4 aut
700	0		\|a Jingxun Wu \|e verfasserin \|4 aut
700	0		\|a Jin Zhou \|e verfasserin \|4 aut
700	0		\|a Zhengfei Zhu \|e verfasserin \|4 aut
700	0		\|a Weiwei Pan \|e verfasserin \|4 aut
700	0		\|a Xiaowei Dong \|e verfasserin \|4 aut
700	0		\|a Fei Pang \|e verfasserin \|4 aut
700	0		\|a Kai Wang \|e verfasserin \|4 aut
700	0		\|a Chao Yao \|e verfasserin \|4 aut
700	0		\|a Guomin Lin \|e verfasserin \|4 aut
700	0		\|a Site Li \|e verfasserin \|4 aut
700	0		\|a Zhi Yang \|e verfasserin \|4 aut
700	0		\|a Jiancheng Luo \|e verfasserin \|4 aut
700	0		\|a Hongtao Jia \|e verfasserin \|4 aut
700	0		\|a Xiuqing Nie \|e verfasserin \|4 aut
700	0		\|a Liping Wang \|e verfasserin \|4 aut
700	0		\|a Youcai Zhu \|e verfasserin \|4 aut
700	0		\|a Xiao Hu \|e verfasserin \|4 aut
700	0		\|a Yanru Xie \|e verfasserin \|4 aut
700	0		\|a Xinqing Lin \|e verfasserin \|4 aut
700	0		\|a Jing Cai \|e verfasserin \|4 aut
700	0		\|a Yang Xia \|e verfasserin \|4 aut
700	0		\|a Huijing Feng \|e verfasserin \|4 aut
700	0		\|a Lin Wang \|e verfasserin \|4 aut
700	0		\|a Yingying Du \|e verfasserin \|4 aut
700	0		\|a Wang Yao \|e verfasserin \|4 aut
700	0		\|a Xuefei Shi \|e verfasserin \|4 aut
700	0		\|a Xiaomin Niu \|e verfasserin \|4 aut
700	0		\|a Dongmei Yuan \|e verfasserin \|4 aut
700	0		\|a Yanwen Yao \|e verfasserin \|4 aut
700	0		\|a Jing Kang \|e verfasserin \|4 aut
700	0		\|a Jiatao Zhang \|e verfasserin \|4 aut
700	0		\|a Chao Zhang \|e verfasserin \|4 aut
700	0		\|a Wenbin Gao \|e verfasserin \|4 aut
700	0		\|a Jianhui Huang \|e verfasserin \|4 aut
700	0		\|a Yinbin Zhang \|e verfasserin \|4 aut
700	0		\|a Pingli Sun \|e verfasserin \|4 aut
700	0		\|a Hong Wang \|e verfasserin \|4 aut
700	0		\|a Mingxiang Ye \|e verfasserin \|4 aut
700	0		\|a Dong Wang \|e verfasserin \|4 aut
700	0		\|a Zhaofeng Wang \|e verfasserin \|4 aut
700	0		\|a Bing Wan \|e verfasserin \|4 aut
700	0		\|a Donglai Lv \|e verfasserin \|4 aut
700	0		\|a Genhua Yu \|e verfasserin \|4 aut
700	0		\|a Lin Shi \|e verfasserin \|4 aut
700	0		\|a Yuanli Xia \|e verfasserin \|4 aut
700	0		\|a Feng Gao \|e verfasserin \|4 aut
700	0		\|a Xiaochen Zhang \|e verfasserin \|4 aut
700	0		\|a Tao Xu \|e verfasserin \|4 aut
700	0		\|a Wei Zhou \|e verfasserin \|4 aut
700	0		\|a Haixia Wang \|e verfasserin \|4 aut
700	0		\|a Zhefeng Liu \|e verfasserin \|4 aut
700	0		\|a Nong Yang \|e verfasserin \|4 aut
700	0		\|a Lin Wu \|e verfasserin \|4 aut
700	0		\|a Qiming Wang \|e verfasserin \|4 aut
700	0		\|a Guansong Wang \|e verfasserin \|4 aut
700	0		\|a Zhuan Hong \|e verfasserin \|4 aut
700	0		\|a Jiandong Wang \|e verfasserin \|4 aut
700	0		\|a Meiyu Fang \|e verfasserin \|4 aut
700	0		\|a Yong Fang \|e verfasserin \|4 aut
700	0		\|a Yiping Zhang \|e verfasserin \|4 aut
700	0		\|a Yong Song \|e verfasserin \|4 aut
700	0		\|a Shenglin Ma \|e verfasserin \|4 aut
700	0		\|a Wenfeng Fang \|e verfasserin \|4 aut
700	0		\|a Yuanzhi Lu \|e verfasserin \|4 aut
773	0	8	\|i In \|t Thoracic Cancer \|d Wiley, 2015 \|g 14(2023), 1, Seite 91-104 \|w (DE-627)DOAJ000142220 \|x 17597714 \|7 nnns
773	1	8	\|g volume:14 \|g year:2023 \|g number:1 \|g pages:91-104
856	4	0	\|u https://doi.org/10.1111/1759-7714.14743 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/e1bf776745ce4a09834d865a24396c56 \|z kostenfrei
856	4	0	\|u https://doi.org/10.1111/1759-7714.14743 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1759-7706 \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1759-7714 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a GBV_DOAJ
951			\|a AR
952			\|d 14 \|j 2023 \|e 1 \|h 91-104

Chinese expert consensus on the diagnosis and treatment of HER2‐altered non–small cell lung cancer

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände